Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study

Lise Høj Omland; Henriette Lindberg; Andreas Carus; Anne Birgitte Als; Niels Viggo Jensen; Gry A. Taarnhøj; Redas Trepiakas; Charlotte Arneboe Suetta; Lars Omland; Helle Pappot

doi:10.1016/j.euros.2020.12.002

Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study

Lise Høj Omland, Henriette Lindberg, Andreas Carus, Anne Birgitte Als, Niels Viggo Jensen, Gry A. Taarnhøj, Redas Trepiakas, Charlotte Arneboe Suetta, Lars Omland, Helle Pappot

14 Citations (Scopus)

Abstract

Background: Real-world treatment patterns and survival outcomes of locally advanced, unresectable, and metastatic urinary tract cancer (mUTC) patients have not previously been studied in a nationwide, population-based cohort.

Objective: To describe treatment patterns and survival outcomes in mUTC patients treated in the real-world clinical setting.

Design setting and participants: This nationwide, population-based study included all mUTC patients initiating first-line chemotherapy at Danish oncology departments from January 2010 to March 2016. Data were retrospectively obtained from electronic medical records.

Outcome measurements and statistical analysis: Outcome measurements were descriptive. Kaplan-Meier was used for survival analysis.

Results and limitations: Of 952 patients included in the study, 46.2% initiated standard gemcitabine/cisplatin (GC) and 21.1% gemcitabine/carboplatin (CaG); the remaining patients initiated other treatment regimens. Median follow-up was 11.6 mo. The overall response rate and disease control rate were 43.0% and 61.7% in all patients, 51.4% and 69.1% in GC-treated patients, and 34.4% and 58.8% in CaG-treated patients, respectively. Median overall survival (OS) was 11.7 (95% confidence interval [CI]: 10.8-12.5) mo in all patients, 14.0 (95% CI: 12.5-15.5) mo in GC-treated patients, and 9.8 (95% CI: 8.7-10.9) mo in CaG-treated patients. Limitations include the retrospective study design.

Conclusions: Real-world mUTC patients are older and less fit than patients enrolled in clinical trials; despite this, tumor responses and survival are comparable. Survival in our patient cohort is also comparable with that reported from other real-world studies in this patient group.

Patient summary: We studied treatment patterns and survival in urinary tract cancer patients receiving chemotherapy in the real-world clinical practice. Survival in our patient cohort was comparable with that reported from clinical trials and other real-world studies in this patient group.

Original language	English
Journal	European Urology Open Science
Volume	24
Pages (from-to)	1-8
Number of pages	8
ISSN	2666-1683
DOIs	https://doi.org/10.1016/j.euros.2020.12.002
Publication status	Published - 2021

Keywords

Chemotherapy
First-line treatment
Real-world treatment
Urinary tract cancer

Access to Document

10.1016/j.euros.2020.12.002

Fingerprint

Dive into the research topics of 'Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study'. Together they form a unique fingerprint.

Cite this

Omland, L. H., Lindberg, H., Carus, A., Als, A. B., Jensen, N. V., Taarnhøj, G. A., Trepiakas, R., Suetta, C. A., Omland, L., & Pappot, H. (2021). Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study. European Urology Open Science, 24, 1-8. https://doi.org/10.1016/j.euros.2020.12.002

Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study. / Omland, Lise Høj; Lindberg, Henriette; Carus, Andreas et al.
In: European Urology Open Science, Vol. 24, 2021, p. 1-8.

Research output: Contribution to journal › Journal article › Research › peer-review

Omland, LH, Lindberg, H, Carus, A, Als, AB, Jensen, NV, Taarnhøj, GA, Trepiakas, R, Suetta, CA , Omland, L & Pappot, H 2021, 'Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study', European Urology Open Science, vol. 24, pp. 1-8. https://doi.org/10.1016/j.euros.2020.12.002

Omland LH, Lindberg H, Carus A, Als AB, Jensen NV, Taarnhøj GA et al. Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study. European Urology Open Science. 2021;24:1-8. doi: 10.1016/j.euros.2020.12.002

@article{084af30d0b004bb79f074dc270ba85e8,

title = "Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study",

abstract = "Background: Real-world treatment patterns and survival outcomes of locally advanced, unresectable, and metastatic urinary tract cancer (mUTC) patients have not previously been studied in a nationwide, population-based cohort.Objective: To describe treatment patterns and survival outcomes in mUTC patients treated in the real-world clinical setting.Design setting and participants: This nationwide, population-based study included all mUTC patients initiating first-line chemotherapy at Danish oncology departments from January 2010 to March 2016. Data were retrospectively obtained from electronic medical records.Outcome measurements and statistical analysis: Outcome measurements were descriptive. Kaplan-Meier was used for survival analysis.Results and limitations: Of 952 patients included in the study, 46.2% initiated standard gemcitabine/cisplatin (GC) and 21.1% gemcitabine/carboplatin (CaG); the remaining patients initiated other treatment regimens. Median follow-up was 11.6 mo. The overall response rate and disease control rate were 43.0% and 61.7% in all patients, 51.4% and 69.1% in GC-treated patients, and 34.4% and 58.8% in CaG-treated patients, respectively. Median overall survival (OS) was 11.7 (95% confidence interval [CI]: 10.8-12.5) mo in all patients, 14.0 (95% CI: 12.5-15.5) mo in GC-treated patients, and 9.8 (95% CI: 8.7-10.9) mo in CaG-treated patients. Limitations include the retrospective study design.Conclusions: Real-world mUTC patients are older and less fit than patients enrolled in clinical trials; despite this, tumor responses and survival are comparable. Survival in our patient cohort is also comparable with that reported from other real-world studies in this patient group.Patient summary: We studied treatment patterns and survival in urinary tract cancer patients receiving chemotherapy in the real-world clinical practice. Survival in our patient cohort was comparable with that reported from clinical trials and other real-world studies in this patient group.",

keywords = "Chemotherapy, First-line treatment, Real-world treatment, Urinary tract cancer",

author = "Omland, {Lise H{\o}j} and Henriette Lindberg and Andreas Carus and Als, {Anne Birgitte} and Jensen, {Niels Viggo} and Taarnh{\o}j, {Gry A.} and Redas Trepiakas and Suetta, {Charlotte Arneboe} and Lars Omland and Helle Pappot",

year = "2021",

doi = "10.1016/j.euros.2020.12.002",

language = "English",

volume = "24",

pages = "1--8",

journal = "European Urology Open Science",

issn = "2666-1683",

publisher = "Elsevier",

}

TY - JOUR

T1 - Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study

AU - Omland, Lise Høj

AU - Lindberg, Henriette

AU - Carus, Andreas

AU - Als, Anne Birgitte

AU - Jensen, Niels Viggo

AU - Taarnhøj, Gry A.

AU - Trepiakas, Redas

AU - Suetta, Charlotte Arneboe

AU - Omland, Lars

AU - Pappot, Helle

PY - 2021

Y1 - 2021

N2 - Background: Real-world treatment patterns and survival outcomes of locally advanced, unresectable, and metastatic urinary tract cancer (mUTC) patients have not previously been studied in a nationwide, population-based cohort.Objective: To describe treatment patterns and survival outcomes in mUTC patients treated in the real-world clinical setting.Design setting and participants: This nationwide, population-based study included all mUTC patients initiating first-line chemotherapy at Danish oncology departments from January 2010 to March 2016. Data were retrospectively obtained from electronic medical records.Outcome measurements and statistical analysis: Outcome measurements were descriptive. Kaplan-Meier was used for survival analysis.Results and limitations: Of 952 patients included in the study, 46.2% initiated standard gemcitabine/cisplatin (GC) and 21.1% gemcitabine/carboplatin (CaG); the remaining patients initiated other treatment regimens. Median follow-up was 11.6 mo. The overall response rate and disease control rate were 43.0% and 61.7% in all patients, 51.4% and 69.1% in GC-treated patients, and 34.4% and 58.8% in CaG-treated patients, respectively. Median overall survival (OS) was 11.7 (95% confidence interval [CI]: 10.8-12.5) mo in all patients, 14.0 (95% CI: 12.5-15.5) mo in GC-treated patients, and 9.8 (95% CI: 8.7-10.9) mo in CaG-treated patients. Limitations include the retrospective study design.Conclusions: Real-world mUTC patients are older and less fit than patients enrolled in clinical trials; despite this, tumor responses and survival are comparable. Survival in our patient cohort is also comparable with that reported from other real-world studies in this patient group.Patient summary: We studied treatment patterns and survival in urinary tract cancer patients receiving chemotherapy in the real-world clinical practice. Survival in our patient cohort was comparable with that reported from clinical trials and other real-world studies in this patient group.

AB - Background: Real-world treatment patterns and survival outcomes of locally advanced, unresectable, and metastatic urinary tract cancer (mUTC) patients have not previously been studied in a nationwide, population-based cohort.Objective: To describe treatment patterns and survival outcomes in mUTC patients treated in the real-world clinical setting.Design setting and participants: This nationwide, population-based study included all mUTC patients initiating first-line chemotherapy at Danish oncology departments from January 2010 to March 2016. Data were retrospectively obtained from electronic medical records.Outcome measurements and statistical analysis: Outcome measurements were descriptive. Kaplan-Meier was used for survival analysis.Results and limitations: Of 952 patients included in the study, 46.2% initiated standard gemcitabine/cisplatin (GC) and 21.1% gemcitabine/carboplatin (CaG); the remaining patients initiated other treatment regimens. Median follow-up was 11.6 mo. The overall response rate and disease control rate were 43.0% and 61.7% in all patients, 51.4% and 69.1% in GC-treated patients, and 34.4% and 58.8% in CaG-treated patients, respectively. Median overall survival (OS) was 11.7 (95% confidence interval [CI]: 10.8-12.5) mo in all patients, 14.0 (95% CI: 12.5-15.5) mo in GC-treated patients, and 9.8 (95% CI: 8.7-10.9) mo in CaG-treated patients. Limitations include the retrospective study design.Conclusions: Real-world mUTC patients are older and less fit than patients enrolled in clinical trials; despite this, tumor responses and survival are comparable. Survival in our patient cohort is also comparable with that reported from other real-world studies in this patient group.Patient summary: We studied treatment patterns and survival in urinary tract cancer patients receiving chemotherapy in the real-world clinical practice. Survival in our patient cohort was comparable with that reported from clinical trials and other real-world studies in this patient group.

KW - Chemotherapy

KW - First-line treatment

KW - Real-world treatment

KW - Urinary tract cancer

UR - http://www.scopus.com/inward/record.url?scp=85098134098&partnerID=8YFLogxK

U2 - 10.1016/j.euros.2020.12.002

DO - 10.1016/j.euros.2020.12.002

M3 - Journal article

C2 - 34337488

SN - 2666-1683

VL - 24

SP - 1

EP - 8

JO - European Urology Open Science

JF - European Urology Open Science

ER -

Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this